Roche has agreed to pay Zymeworks $55 million upfront for an exclusive global license to ZW209, a trispecific T cell engager the companies plan to develop for lung cancer. If the program advances, Zymeworks could receive another $40 million when ZW209 enters Phase 1b, plus up to $718 million in development, commercial and sales milestones and high-single-digit to mid-teen royalties on future net sales.
The asset is still early. ZW209 is in Phase 1a after receiving the regulatory clearances needed to start clinical testing, and Zymeworks will run that monotherapy study in collaboration with Roche, with Roche funding the trial. Roche will take over subsequent global development, regulatory activities and commercialization.
Why Roche is buying early
ZW209 is designed to bind DLL3 on tumor cells while also engaging CD3 and CD28 on T cells. That makes it a trispecific variation on the DLL3xCD3 approach already validated commercially and regulatorily by Amgen’s Imdelltra, which won FDA approval in small cell lung cancer in 2024. Fierce Biotech also noted that Boehringer Ingelheim is advancing a rival DLL3xCD3 bispecific in Phase 3.
Zymeworks’ argument is that the extra arm may improve on the rate and depth of responses seen with bispecific DLL3 drugs. Preclinical data the company presented last year compared ZW209 with a bispecific T-cell engager and, according to Fierce Biotech, showed improved T-cell fitness and antitumor activity, including potent antitumor activity in multiple humanized small cell lung cancer xenograft models.
That rationale is tied to a known challenge in small cell lung cancer. Zymeworks has said the tumor type is characterized by low T-cell infiltration and poor T-cell function, and that T cells can become unresponsive when stimulated through CD3 alone. Adding CD28 is intended to help address those limits on antitumor responses, though that still needs human validation.
Early development and strategic fit
The ongoing Phase 1a study is designed to evaluate safety, tolerability, pharmacokinetics and early efficacy in patients with advanced solid tumors, including small cell lung cancer and DLL3-expressing neuroendocrine tumors. That means Roche is buying into a platform hypothesis as much as a single molecule: whether a trispecific format can produce better functional T-cell activity than current bispecific designs.
The deal also fits Roche’s broader interest in small cell lung cancer. Fierce Biotech noted that Roche already sells Tecentriq in the tumor type and is developing an antibody-drug conjugate with MediLink. Within that context, ZW209 gives Roche another shot on goal in an aggressive cancer where incremental efficacy differences can matter commercially.
For Zymeworks, the transaction supports a business model built around licensing internally generated assets while retaining downstream economics. Leerink Partners said the agreement validates the biotech’s royalty-based approach: monetize internal innovation, move development costs to partners and preserve participation in future commercial upside. BioSpace pointed to Zymeworks’ earlier partnerships with Jazz Pharmaceuticals for Ziihera and with Johnson & Johnson for six bispecific antibodies as examples of that strategy, while also noting that Bristol Myers Squibb ended the final asset under the older Zymeworks-Celgene alliance in April.
The signal here is less about near-term revenue than portfolio design. Roche is continuing to assemble external oncology options at an early stage, and Zymeworks is showing it can keep turning platform work into milestone-bearing partnerships even after losing a major collaborator. If ZW209 produces encouraging Phase 1a data, the value will extend beyond this program because it would test whether trispecific T-cell engagers can offer a credible upgrade path over established bispecifics.
